{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T06:23:43Z","timestamp":1791699823271,"version":"4.3.4"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020624","name":"NIHR Nottingham Biomedical Research Centre","doi-asserted-by":"publisher","award":["RC48LF"],"award-info":[{"award-number":["RC48LF"]}],"id":[{"id":"10.13039\/501100020624","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2025,6,17]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Antipsychotic treatments require physical health monitoring (PHM), especially among children and young people (CYP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>For CYP aged 5-17, to investigate recorded indications for antipsychotics prescribing and first-treatment durations, and, for psychosis, bipolar disorder, autism spectrum disorder (ASD) and Tourette\u2019s syndrome, recorded levels of PHM for CYP with antipsychotics prescriptions and those without.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All CYP registered with QResearch English general practices between 2006 and 2021 were considered. To quantify PHM, 2158 CYP with antipsychotics prescriptions and 22 151 CYP with a condition but no prescriptions were followed for 2 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Findings<\/jats:title>\n                  <jats:p>47% (2363) of CYP with antipsychotics prescriptions had a recorded mental health condition of interest (of which 62% were ASD). 19% (921) had no relevant indication. For patients with ASD and Tourette syndrome, top quartiles for initial exposure to antipsychotics were &gt;10 months. Recorded PHM was generally low, with over 50% of CYP showing no blood test during the 2-year follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Coverage of best practice is uneven across the condition-related national CYP guidelines, and this requires improvement. However, we suspect some apparently poor adherence to best practice also derives from treatment complexities and associated data flows leading to gaps in the encoded general practice data. To audit more exactly clinical practice against guidelines, we propose qualitative studies, targeted to cover the full range of local circumstances, nationally.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical implications<\/jats:title>\n                  <jats:p>General practices should be encouraged to prioritise encoding of all treatment data. Development of one central gold-standard set of recommendations for antipsychotics use could encourage better adherence levels across conditions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjment-2024-301287","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T16:23:30Z","timestamp":1752510210000},"page":"e301287","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Guidelines and practice on antipsychotics prescribing and physical health monitoring in children and young people: a cohort study using primary care data"],"prefix":"10.1136","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3030-5257","authenticated-orcid":false,"given":"Yana","family":"Vinogradova","sequence":"first","affiliation":[{"name":"Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4009-020X","authenticated-orcid":false,"given":"Ruth H","family":"Jack","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5470-276X","authenticated-orcid":false,"given":"Vibhore","family":"Prasad","sequence":"additional","affiliation":[{"name":"Centre for Academic Primary Care, University of Nottingham, Nottingham, UK"},{"name":"Department of Population Health Sciences, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2327-3306","authenticated-orcid":false,"given":"Carol","family":"Coupland","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Morriss","sequence":"additional","affiliation":[{"name":"Mental Health and Neuroscience, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1083-6744","authenticated-orcid":false,"given":"Chris","family":"Hollis","sequence":"additional","affiliation":[{"name":"University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"2025082702295726000_28.1.e301287.1","doi-asserted-by":"publisher","DOI":"10.1002\/j.2051-5545.2011.tb00014.x"},{"key":"2025082702295726000_28.1.e301287.2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.9740\/mhc.2021.11.311","article-title":"Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome","volume":"11","author":"DeJongh","year":"2021","journal-title":"Ment Health Clin"},{"key":"2025082702295726000_28.1.e301287.3","unstructured":"National Institute for Clinical Excellence . Psychosis and schizophrenia in children and young people: recognition and management. NICE guidline CG155. 2018."},{"key":"2025082702295726000_28.1.e301287.4","unstructured":"National Institute for Clinical Excellence . Bipolar disorder: assessment and management NICE guidline CG185. 2020."},{"key":"2025082702295726000_28.1.e301287.5","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamapsychiatry.2013.2053","article-title":"Antipsychotics and the risk of type 2 diabetes mellitus in children and youth","volume":"70","author":"Bobo","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"2025082702295726000_28.1.e301287.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549"},{"key":"2025082702295726000_28.1.e301287.7","unstructured":"NHS Clinical Commissioners . Responsibility for prescribing between primary & secondary\/tertiary care. NHS England; 2018."},{"key":"2025082702295726000_28.1.e301287.8","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s11096-023-01642-5","article-title":"Guideline adherence for cardiometabolic monitoring of patients prescribed antipsychotic medications in primary care: a retrospective observational study","volume":"45","author":"Ali","year":"2023","journal-title":"Int J Clin Pharm"},{"key":"2025082702295726000_28.1.e301287.9","doi-asserted-by":"publisher","DOI":"10.1016\/s2215-0366(22)00404-7"},{"key":"2025082702295726000_28.1.e301287.10","unstructured":"National Institute for Clinical Excellence . Autism spectrum disorder in under 19s: support and management. NICE guideline CG170. 2021."},{"key":"2025082702295726000_28.1.e301287.11","unstructured":"National Institute for Clinical Excellence . Suspected neurological conditions: recognition and referral. NICE CG127. 2019."},{"key":"2025082702295726000_28.1.e301287.12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1089\/cap.2017.0003","article-title":"Characteristics of Children Prescribed Antipsychotics: Analysis of Routinely Collected Data","volume":"28","author":"Brophy","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2025082702295726000_28.1.e301287.13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/00048674211009620","article-title":"Monitoring of metabolic side-effects in children and adolescents prescribed antipsychotic medication: A systematic review","volume":"55","author":"Mead","year":"2021","journal-title":"Aust N Z J Psychiatry"},{"key":"2025082702295726000_28.1.e301287.14","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1089\/cap.2017.0034","article-title":"Improving Cardiometabolic Monitoring of Children on Antipsychotics","volume":"27","author":"Cotes","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2025082702295726000_28.1.e301287.15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1078390317752444","article-title":"Improving Adherence to Atypical Antipsychotic Agent Screening Guidelines in Pediatric Patients: A Quality Improvement Project Within an Integrated Community Mental Health Setting","volume":"24","author":"Featherston","year":"2018","journal-title":"J Am Psychiatr Nurses Assoc"},{"key":"2025082702295726000_28.1.e301287.16","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-7-28","article-title":"A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients","volume":"7","author":"Mackin","year":"2007","journal-title":"BMC Psychiatry"},{"key":"2025082702295726000_28.1.e301287.17","unstructured":"Royal College of Psychiatrists . National clinical audit of psychosis \u2013 national report for the core audit 2018. London Healthcare Quality Improvement Partnership; 2018."},{"key":"2025082702295726000_28.1.e301287.18","unstructured":"Royal College of Psychiatrists . National clinical audit of psychosis \u2013 national report for the early intervention in psychosis audit 2020\/2021. London Healthcare Quality Improvement Partnership; 2021."},{"key":"2025082702295726000_28.1.e301287.19","doi-asserted-by":"crossref","unstructured":"Vinogradova Y , Jack RH , Prasad V , et al . A protocol to assess antipsychotics prescribing and physical health monitoring in children and young people: a cohort study using primary care data from qresearch. medRxiv [Preprint]. doi:10.1101\/2024.07.18.24310326","DOI":"10.1101\/2024.07.18.24310326"},{"key":"2025082702295726000_28.1.e301287.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003215","article-title":"Incidence and prevalence of primary care antidepressant prescribing in children and young people in England, 1998-2017: A population-based cohort study","volume":"17","author":"Jack","year":"2020","journal-title":"PLoS Med"},{"key":"2025082702295726000_28.1.e301287.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02247-x","article-title":"The risk of all-cause and cause-specific mortality in people prescribed mirtazapine: an active comparator cohort study using electronic health records","volume":"20","author":"Joseph","year":"2022","journal-title":"BMC Med"},{"key":"2025082702295726000_28.1.e301287.22","doi-asserted-by":"publisher","DOI":"10.1017\/S0047279400020341"},{"key":"2025082702295726000_28.1.e301287.23","unstructured":"National Health Service . Mental health of children and young people in England 2022 - wave 3 follow up to the 2017 survey. 2022. Available: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/mental-health-of-children-and-young-people-in-england\/2022-follow-up-to-the-2017-survey"},{"key":"2025082702295726000_28.1.e301287.24","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2025082702295726000_28.1.e301287.25","unstructured":"Royal College of Psychiarists . Position statement PS05\/21: stopping the overprescribing of people with intellectual disability, autism or both (STOMP) and supporting treatment and appropriate medication in paediatrics (STAMP). 2021. Available: https:\/\/www.england.nhs.uk\/learning-disabilities\/improving-health\/stomp-stamp\/"},{"key":"2025082702295726000_28.1.e301287.26","unstructured":"NHS UK . Stopping over medication of people with a learning disability and autistic people (STOMP) and supporting treatment and appropriate medication in paediatrics (STAMP). 2024. Available: https:\/\/www.england.nhs.uk\/learning-disabilities\/improving-health\/stomp-stamp\/ [Accessed 30 Jul 2024]."},{"key":"2025082702295726000_28.1.e301287.27","unstructured":"Glover G , Williams R , Branford D , et al . Prescribing of psychotropic drugs to people with learning disabilities and\/or autism by general practitioners in England. Public Health England; 2015."},{"key":"2025082702295726000_28.1.e301287.28","unstructured":"National Institute for Clinical Excellence . Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. NICE guideline NG11. 2015."},{"key":"2025082702295726000_28.1.e301287.29","unstructured":"National Institute for Clinical Excellence . Mental health problems in people with learning disabilities: prevention, assessment and management NICE guideline NG54. 2016."},{"key":"2025082702295726000_28.1.e301287.30","unstructured":"National Institute for Clinical Excellence . Learning disabilities and behaviour that challenges: service design and delivery NICE guidline NG93. 2018."}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2024-301287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:30:15Z","timestamp":1756287015000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2024-301287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7,8]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjment-2024-301287"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2024-301287","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}